China Renaissance’s healthcare fund co-led the round. CDM claims it prices its HIV reagents at about one-third the price of comparable HIV reagents from multinational biopharmas. Curon Biophama, a Sha…
( read original story …)
The Shanghai News
China Renaissance’s healthcare fund co-led the round. CDM claims it prices its HIV reagents at about one-third the price of comparable HIV reagents from multinational biopharmas. Curon Biophama, a Sha…
( read original story …)